Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
- PMID: 11751775
- DOI: 10.1093/jac/49.1.121
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
Abstract
Ceftazidime demonstrates time-dependent killing, which is maximal at 4 x or 5 x MIC for the organism, consequently continuous infusion (CI) has been proposed to ensure adequate ceftazidime concentrations for the entire course of therapy. Severe intra-abdominal infections (IAIs) require surgical or percutaneous drainage for management, and ceftazidime is frequently prescribed. Cardiovascular or metabolic changes and renal or liver dysfunction may alter drug pharmacokinetics during severe IAIs, and no data exist on concentrations of ceftazidime reached in the peritoneal fluid. The objectives here were to determine the pharmacokinetics of ceftazidime during continuous and intermittent administration in patients with severe IAIs, and to measure the concentrations of ceftazidime in the peritoneal exudate. Eighteen surgical patients with severe IAI and a creatinine clearance of >30 mL/min were studied. A non-randomized pilot study of six patients treated with CI alone was followed by a prospective, randomized comparative study of 12 patients. Pilot study patients received ceftazidime 1 g iv followed by a 4.5 g CI over 24 h. Randomized patients received either ceftazidime continuously as above or 1.5 g tds. Samples for pharmacokinetic analyses were collected on days 2 and 4. Ceftazidime concentrations were determined by high-performance liquid chromatography. CI resulted in a mean serum concentration >40 mg/L and a T> 4 x MIC for most pathogens encountered in severe IAIs for >90% of the course of therapy in both serum and peritoneal exudate. Eight-hourly administration resulted in T> 4 x MIC for most pathogens encountered in severe IAIs for >90% of the dosing interval, but in peritoneal exudate for only 44% of the dosing interval. During CI, AUCs in the peritoneal exudate were c. 60% of the concomitant serum AUCs. In critically ill surgical patients with severe IAIs, CI of ceftazidime resulted in more favourable concentrations in serum and peritoneal exudate than 8-hourly bolus infusion.
Similar articles
-
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.Antimicrob Agents Chemother. 1996 Mar;40(3):691-5. doi: 10.1128/AAC.40.3.691. Antimicrob Agents Chemother. 1996. PMID: 8851594 Free PMC article. Clinical Trial.
-
Intermittent bolus dosing of ceftazidime in critically ill patients.J Antimicrob Chemother. 1997 Aug;40(2):269-73. doi: 10.1093/jac/40.2.269. J Antimicrob Chemother. 1997. PMID: 9301994
-
Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.Br J Clin Pharmacol. 2000 Aug;50(2):184-91. doi: 10.1111/j.1365-2125.2000.00179.x. Br J Clin Pharmacol. 2000. PMID: 10930972 Free PMC article. Clinical Trial.
-
Continuous infusion of beta-lactam antibiotics.Clin Pharmacokinet. 1998 Nov;35(5):391-402. doi: 10.2165/00003088-199835050-00004. Clin Pharmacokinet. 1998. PMID: 9839090 Review.
-
Ceftazidime stability and pyridine toxicity during continuous i.v. infusion.Am J Health Syst Pharm. 2019 Feb 1;76(4):200-205. doi: 10.1093/ajhp/zxy035. Am J Health Syst Pharm. 2019. PMID: 30715181 Review.
Cited by
-
A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.Infection. 2009 Aug;37(4):296-305. doi: 10.1007/s15010-009-7108-9. Epub 2009 Jul 23. Infection. 2009. PMID: 19629383 Review.
-
Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Crit Care. 2013 Nov 29;17(6):R279. doi: 10.1186/cc13134. Crit Care. 2013. PMID: 24289230 Free PMC article.
-
Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.Front Pharmacol. 2022 Sep 21;13:964005. doi: 10.3389/fphar.2022.964005. eCollection 2022. Front Pharmacol. 2022. PMID: 36210807 Free PMC article.
-
Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.Antibiotics (Basel). 2021 Sep 24;10(10):1154. doi: 10.3390/antibiotics10101154. Antibiotics (Basel). 2021. PMID: 34680734 Free PMC article. Review.
-
Canadian practice guidelines for surgical intra-abdominal infections.Can J Infect Dis Med Microbiol. 2010 Spring;21(1):11-37. doi: 10.1155/2010/580340. Can J Infect Dis Med Microbiol. 2010. PMID: 21358883 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical